StockData

DHI vs OptimizeRx

DHX and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DHX and OPRX compare

DHI is the larger company, worth 1.5 times as much as OptimizeRx ($184M against $125M).

On earnings, OptimizeRx is cheaper: it trades at 27.7× trailing earnings, against 141× for DHI.

OptimizeRx grew revenue faster over the last twelve months (−5.8% versus −7.3% for DHI).

OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with 0.97% at DHI.

OptimizeRx scores higher on the StockData Score (10 against 4 for DHI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDHXOPRX
Size and price
Market cap$184M$125M
Share price$4.23$6.64
Change, 1 year127%−57.1%
Change, 5 years−22.2%−90.3%
Beta (5Y)1.051.56
Employees270104
StockData Score
Total score410 (better)
Valuation score13 (better)
Growth score02 (better)
Performance score12 (better)
Health score23 (better)
Dividend score00
Valuation
P/E141×27.7× (better)
P/S1.5×1.3× (better)
P/B2.0×1.0× (better)
EV/EBITDA35.0×7.9× (better)
P/FCF9.1×6.8× (better)
FCF yield11.0%14.7% (better)
Fair value$2.07$10.13
Margin of safety−104%34.5% (better)
Growth
Revenue growth (TTM)−7.3%−5.8% (better)
Revenue growth, 5Y average2.8%20.4% (better)
Profitability
Gross margin83.8% (better)73.2%
Operating margin4.9%11.1% (better)
Net margin0.97%4.7% (better)
FCF margin16.2%18.6% (better)
Return on equity1.2%3.7% (better)
Return on invested capital2.4%5.8% (better)
Financial health
Debt / equity0.340.15 (better)
Net debt / EBITDA4.67 (better)−0.33
Interest coverage2.5× (better)2.3×
Current ratio0.445.58 (better)
Altman Z-score1.912.72 (better)
Piotroski F-score38 (better)
Dividends and buybacks
Buyback yield7.1%–
Shareholder yield7.1% (better)0.00%
Ownership
Held by institutions70.5%59.6%
Held by insiders18.6%19.4%
Insider net buying, 12 months−$265K−$18.8K (better)
Short interest, % of float0.88%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.